^
    Back
    Association details:
    Biomarker:CRBN expression
    Cancer:Multiple Myeloma
    Drug:thalidomide (TNF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Med
    Title:

    The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients

    Published date:
    06/18/2021
    Excerpt:
    ...MM patients treated with thalidomide or lenalidomide-based regimens. We found that the expression of CRBN and CUL4A was associated with the superior IMiD-based treatment response (p = 0.007 and p = 0.007, respectively).
    DOI:
    10.3390/jcm10122683